DRUG - Bright Minds Biosciences Inc. News

Discover

DRUG

Bright Minds Biosciences Inc.

79.39

1 x 74.00

1 x 78.80

bid

ask

2.10

2.72%

09:12 AM

timesize

Ytd	1.73%
1y	203.72%

77.75

day range

78.04

25.77

52 week range

123.75

Open	78.04	Prev Close	77.29	Low	77.75	High	78.04	Mkt Cap	599.89M
Vol	1.53K	Avg Vol	313.87K	EPS	-2.44	P/E	-31.68	Forward P/E	N/A
Beta	-5.34	Short Ratio	0.70	Inst. Own	44.28%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-13	50-d Avg	73.23	200-d Avg	75.09	1yr Est	4.87

DRUG News

globenewswire.com

Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or

fool.com

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric

benzinga.com

FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order

https://www.hhs.gov/press-room/fda-accelerates-action-treatments-serious-mental-illness-following-ex

benzinga.com

'Trump To Sign Executive Order On Psychedelic Drug Used Abroad To Treat PTSD' - CBS News Exclusive

https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/

defenseworld.net

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Moderate Buy” from B

Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been given a consensus recommenda

globenewswire.com

Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or

defenseworld.net

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of “Moderate Buy” from

Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been assigned an average rating o

globenewswire.com

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)

globenewswire.com

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)

seekingalpha.com

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resi

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

globenewswire.com

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)

benzinga.com

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Bright Minds Biosciences Inc. (NASDAQ: DRUG) stock is trading higher on Tuesday after the company sh

benzinga.com

Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Movi

globenewswire.com

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 i

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG)

proactiveinvestors.com

Bright Mind Biosciences shares surge on positive epilepsy drug trial results

Shares of Bright Minds Biosciences Inc (NASDAQ: DRUG, CSE:DRUG) jumped almost 25% after the company

globenewswire.com

Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developme

– Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Mi

defenseworld.net

Bright Minds Biosciences (NASDAQ:DRUG) Trading 4.2% Higher – Here’s What Happened

Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report)'s share price rose 4.2% during tradin

defenseworld.net

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) have received an average ra

proactiveinvestors.com

Bright Minds Biosciences has standout year with epilepsy drug in Phase II trials

For three decades, central nervous system (CNS) drug development was a tough space for investors, sc

zacks.com

Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why

Bright Minds Biosciences Inc. (DRUG) made it through our "Recent Price Strength" screen and could be

globenewswire.com

Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or

zacks.com

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before

The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in Br

fool.com

Why Bright Minds Biosciences Stock Topped the Market on Monday

Days after starting a new investigational program, it announced four appointments to its scientific

benzinga.com

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 369 companies hit new 52-week lows.

benzinga.com

Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

benzinga.com

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 729 companies set new 52-week lows.